Infinity Pharmaceuticals Performance

INFI -- USA Stock  

USD 2.04  0.02  0.99%

On a scale of 0 to 100 Infinity Pharmaceuticals holds performance score of 12. The company retains Market Volatility (i.e. Beta) of 5.0138 which attests that as market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Infinity Pharmaceuticals will likely underperform.. Although it is vital to follow to Infinity Pharmaceuticals current price history, it is good to be conservative about what you can actually do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. We have found twenty-eight technical indicators for Infinity Pharmaceuticals which you can use to evaluate performance of the corporation. Please utilizes Infinity Pharmaceuticals Information Ratio, Downside Variance, Day Median Price, as well as the relationship between Treynor Ratio and Kurtosis to make a quick decision on weather Infinity Pharmaceuticals current trending patterns will revert.
 Time Horizon     30 Days    Login   to change

Infinity Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  174.00  in Infinity Pharmaceuticals on June 16, 2018 and sell it today you would earn a total of  29.50  from holding Infinity Pharmaceuticals or generate 16.95% return on investment over 30 days. Infinity Pharmaceuticals is currently generating 0.8855% of daily expected returns and assumes 4.7842% risk (volatility on return distribution) over the 30 days horizon. In different words, 43% of equities are less volatile than Infinity Pharmaceuticals and 84% of traded equity instruments are projected to make higher returns than the company over the 30 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 30 days, Infinity Pharmaceuticals is expected to generate 7.22 times more return on investment than the market. However, the company is 7.22 times more volatile than its market benchmark. It trades about 0.19 of its potential returns per unit of risk. The DOW is currently generating roughly 0.01 per unit of risk.

Infinity Pharmaceuticals Market Risk Analysis

Sharpe Ratio = 0.1851
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsINFI
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns

Infinity Pharmaceuticals Relative Performance Indicators

Estimated Market Risk
 4.78
  actual daily
 
 57 %
of total potential
  
Expected Return
 0.89
  actual daily
 
 16 %
of total potential
  
Risk-Adjusted Return
 0.19
  actual daily
 
 12 %
of total potential
  
Based on monthly moving average Infinity Pharmaceuticals is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Infinity Pharmaceuticals by adding it to a well-diversified portfolio.

Performance Rating

Infinity Pharmaceuticals Risk Adjusted Performance Analysis
12 

Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in Infinity Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 30 days.

Infinity Pharmaceuticals Alerts

Equity Alerts and Improvement Suggestions
Infinity Pharmaceuticals appears to be very risky and stock price may revert if volatility continues
Infinity Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 6 M. Net Loss for the year was (40.81 M) with loss before overhead, payroll, taxes, and interest of (14.83 M).
INFINITY PHARMACE currently holds about 47.81 M in cash with (28.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85.
Roughly 62.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Purchase by Bvf Partners L P of 36825 shares of Infinity Pharmaceuticals
Please also check Risk vs Return Analysis. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.